Rationale: Effective neovascularization is crucial for recovery after cardiovascular events. Objective: Because microRNAs regulate expression of up to several hundred target genes, we set out to identify microRNAs that target genes in all pathways of the multifactorial neovascularization process. Using www.targetscan. org, we performed a reverse target prediction analysis on a set of 197 genes involved in neovascularization. We found enrichment of binding sites for 27 microRNAs in a single microRNA gene cluster. Microarray analyses showed upregulation of 14q32 microRNAs during neovascularization in mice after single femoral artery ligation.
N eovascularization is the body's natural repair mechanism to restore blood flow to ischemic tissues after a cardiovascular event. Neovascularization is comprised of arteriogenesis and angiogenesis. Arteriogenesis is defined by the maturation of pre-existing collateral arterioles into mature collateral arteries. 1 Arteriogenesis takes place upstream of the ischemic area and is driven by increases in shear stress, rather than ischemia. When a nearby artery becomes occluded, blood is forced through collateral arterioles. The increases in flow, shear stress, and circumferential stretch activate the arteriolar wall and trigger an inflammatory response that leads to rearrangement of the extracellular matrix and outward remodeling of the arteriole. Angiogenesis is defined by the sprouting of new capillaries from existing blood vessels in the microcirculation. 2 Angiogenesis is driven solely by ischemia. Via, among others, the hypoxiainducible factor 1α, ischemia leads to upregulation of proangiogenic growth factors, triggering nearby vascular endothelial cells to form sprouts toward the ischemic area. Ischemia also induces gene transcription of proinflammatory chemokines and cytokines, which trigger a local inflammatory reaction. As to arteriogenesis, inflammation is crucial to angiogenesis too, facilitating extracellular matrix rearrangement, cell growth, and proliferation.
Both arteriogenesis and angiogenesis are highly multifactorial processes, and yet clinical trials aiming to induce neovascularization in patients with occlusive arterial disease have so far only focused on single-factor therapeutics, such as growth factors (eg, vascular endothelial growth factor A [VEGFA] and basic fibroblast growth factor [bFGF] ). Unfortunately, these trials were less successful than anticipated. 1, 3, 4 Growth factors only target 1 of multiple processes required for efficient neovascularization. Therefore, there is a need for novel proarteriogenic and proangiogenic factors that can act as master switches in neovascularization.
MicroRNAs are endogenous RNA molecules that downregulate expression of their target genes. 5 MicroRNAs do not completely silence their target genes, but rather downtune their expression. However, because each microRNA has multiple, up to several hundred, target genes, changes in microR-NA expression can have a major impact. Inhibition of a single microRNA can thus lead to activation of entire multifactorial physiological processes.
Several studies have been published on the effects of microRNA inhibition on neovascularization, but in general, the focus of these studies lies with angiogenesis alone, not arteriogenesis. [6] [7] [8] [9] [10] [11] [12] [13] [14] In the present study, we exploited the master switch character of microRNAs to identify microRNAs that play a regulatory role in neovascularization as a whole, including both angiogenesis and arteriogenesis. We performed a reverse target prediction (RTP) analysis on a set of ≈200 genes involved in all facets of angiogenesis and arteriogenesis, aiming to identify microRNAs that can target multiple neovascularization genes. We found enrichment of putative target sites for 27 microRNAs that are all located in 1 large microRNA gene cluster. This microRNA gene cluster consists of >50 microRNAs, highly conserved in mammals, that are transcribed from 1 polycystronic site on the imprinted DLK1 region on the long arm of human chromosome 14 (14q32; chromosome 12F1 in mice; Figure 1 ).
The 14q32 microRNA gene cluster was first discovered in 2004 by Seitz et al. 15 Using in silico DNA sequence analyses, Seitz et al 15 were able to predict 46 of the currently known 54 human 14q32 microRNA genes (61 in mice). The cluster is highly conserved in mammals, but not in other vertebrates or in invertebrates. Although many microRNAs are transcribed from polycistronic microRNA gene clusters, the 14q32 cluster is among the largest known microRNA gene clusters in any species. The facts that the cluster is so specifically conserved in mammals and that it is located in a strictly regulated, imprinted region of the genome hint at its biological importance. Indeed, almost all 14q32 microRNAs have been implicated in human disease, many of them in cardiovascular disease. 16 Interestingly, most 14q32 microRNAs are predicted to regulate focal adhesion and extracellular matrix interactions, both crucial in vascular remodeling. Knockout of the cluster, via knockout of the Meg3 locus, 17, 18 led to overexpression of several proangiogenic genes, including Vegfa and Dll4, and drastically increased vascular capillary density in mouse embryos. 19 A recent study showed that the cluster is under transcriptional control of a binding site for the myocyte enhancer factor 2A (MEF2A), 20 a transcription factor known to influence vascular remodeling. 21, 22 We show here that inhibition of individual 14q32 microRNAs leads to improvements in postischemic blood flow recovery in vivo.
Methods

Reverse Target Prediction
To identify microRNAs that are involved in arteriogenesis and angiogenesis, an in silico RTP was performed. A selection was made of 127 genes known from literature and previous studies within our group to play important roles in arteriogenesis and angiogenesis (Online Table IA ). To ensure the master switch character of the identified microRNAs, we selected target genes covering all aspects of vascular remodeling: endothelial activation, smooth muscle cell proliferation, extracellular matrix rearrangement, chemokines and cytokines and their receptors, growth factors and their receptors, the natural killer complex, proarteriogenic and proangiogenic transcription factors, and signaling molecules (Online Table IA ). We then used www.targetscan.org to, for each individual gene, generate a list of all microRNAs predicted to target these 127 genes. Each list, no restrictions were applied, was copied into a spreadsheet, and for each microRNA we simply counted the number of times it was present in the file.
To confirm the relevance of our findings, we selected an additional 70 genes that we found upregulated using microarray analysis, at the site of active arteriogenesis, the adductor muscle group, in C57Bl/6 mice subjected to single ligation of the left femoral artery (Online Table IIA ). We repeated the RTP for these 70 genes and looked for similarities in identified microRNAs between the 2 RTPs (for 14q32 microRNAs, see Online Table III) .
Both RTPs were performed looking for microRNA-binding sites in human target genes to ensure clinical relevance. Conservation between human and murine target sites was checked to confirm the validity of our murine model of hindlimb ischemia (HLI; for 14q32 microRNAs, see Online Table IV ).
The procedure of RTP is schematically summarized in Online Figure I .
MicroRNA Inhibitors
Antagomirs were designed with perfect reverse complementarity to the mature target microRNA sequence and purchased from VBC Biotech (Vienna, Austria). Antagomirs were made up of a singlestranded O-methyl-modified RNA strand with 5′-end and 3′-end phosporothioate linkages and a 3′-end cholesterol tail.
Gene silencing oligonucleotides (GSOs) were designed with perfect reverse complementarity to the mature target microRNA sequence and synthesized at Idera Pharmaceuticals (Cambridge, MA). 23 As a negative control, a scrambled sequence was used, designed not to target any known murine microRNA. GSOs were made up of 2 single-stranded O-methyl-modified DNA strands, linked together at their 5′ ends by a phosphorothioate linker. Shielding the 5′-end of the single-stranded oligonucleotides prevents activation of the innate immune system via Toll-like receptors; the double DNA strand increases specificity for the target microRNA.
Sequences of all antagomirs and GSOs used are given in Online were early (red), late (green), or nonresponders (blue) after hindlimb ischemia induced by single ligation of the femoral artery in healthy C57Bl/6 mice. 14q32 miRs that were not included in the microarray are indicated in purple, and coding (thick bars) and noncoding genes (thin bars) are indicated in black. Human base positions are numbered according to assembly GRCh37.p13, and murine base positions according to GRCm38.p2.
For microRNA inhibition experiments, mice were given a bolus injection of 1 mg (≈40 mg/kg) GSO in PBS or PBS alone via the tail vein (intravenously) 1 day before femoral artery ligation.
Mice were anesthetized by intraperitoneal injection of midazolam (8 mg/kg; Roche Diagnostics), medetomidine (0.4 mg/kg; Orion), and fentanyl (0.08 mg/kg; Janssen Pharmaceuticals). Unilateral HLI was induced by electrocoagulation of the left femoral artery proximal to the superficial epigastric arteries alone (single ligation: model for effective arteriogenesis), or combined with electrocoagulation of the distal femoral artery proximal to the bifurcation of the popliteal and saphenous artery 24 (double ligation: model for severe peripheral arterial disease). After surgery, anesthesia was antagonized with flumazenil (0.7 mg/kg; Fresenius Kabi), atipamezole (3.3 mg/kg; Orion), and buprenorphine (0.2 mg/kg; MSD Animal Health).
Blood flow recovery to the paw was measured over time using laser Doppler perfusion imaging (LDPI; Moore Instruments). Mice were anaesthetized by intraperitoneal injection of midazolam (8 mg/kg) and medetomidine (0.4 mg/kg). Mice were place in a double-glazed pot, perfused with water at 37°C for 5 minutes before each measurement. After LDPI, anesthesia was antagonized by subcutaneous injection of flumazenil (0.7 mg/kg) and atipamezole (3.3 mg/kg). LDPI measurements in the treated paw were normalized to measurements of the untreated paw, as internal control.
Analgesic fentanyl (0.08 mg/kg) was administered subcutaneously after the final LDPI measurement, and mice were euthanized. The adductor, gastrocnemius, and soleus muscles were harvested and either snap-frozen on dry ice or fixed in 4% PFA.
Additional materials and methods are provided in the Online Data Supplement.
Results
Reverse Target Prediction
We performed 2 RTP analyses. In the initial RTP, we included 127 genes that are known to be involved in neovascularization from both literature and our own studies (Online Table  IA ). As anticipated, we observed enrichment of putative binding sites for several microRNAs that were previously reported to influence postischemic neovascularization, including miR-17/92a 9 (29 and 21 putative target genes, respectively), miR-106b/93/25 8, 14 (29, 29 , and 21 putative target genes, respectively), the miR-15a family 10, 11, 25 (26 putative target genes), miR-503 13 (11 putative target genes), and miR-100 7 (2 putative target genes) but not, for example, miR-126. 6 However, more outspoken was the enrichment of putative binding sites for 27 microRNAs from the 14q32 microRNA gene cluster, including miR-329, miR-494, and miR-495 (20, 31, and 44 putative target genes, respectively). All findings of RTP1 are given in Online Tables IB and IC. In the second RTP, we included 70 additional genes that we found upregulated in the early stages of vascular remodeling in murine tissue after HLI induced by single ligation of the femoral artery, a model for effective neovascularization (Online Table IIA ). We again observed enrichment of binding sites for miR-17/92 (8 and 4 putative target genes, respectively), miR-106/93/25 (8, 8 , and 4 putative target genes, respectively), the miR-15a family (3 putative target genes), miR-503 (5 putative target genes), and miR-100 (1 putative target genes). Furthermore, enrichment of binding sites for 26 of the initial 27 identified 14q32 microRNAs was recovered, including miR-329, miR-494, and miR-495 (10, 8, and 7 putative target genes, respectively). All findings of RTP2 are given in Online Table IIB . The findings for 14q32 miRs in RTP1 and RTP2 are summarized in Online Table III. We used human target gene sequences in both RTPs and checked for conservation between human and murine target sites. The 14q32 microRNA gene cluster is highly conserved between mammals, and we found that many, but not all, putative target sites are conserved as well (Online Table IV) .
Microarray
We performed microarray analyses of microRNA expression profiles on the same murine tissue samples used for mRNA microarray analyses. At 24 hours after HLI (single femoral artery ligation), 14q32 miR-494 was the secondmost significantly regulated microRNA of all microRNAs, after miR883a-5p. miR-494 was rapidly upregulated at 24 and at 72 hours; expression normalized after 7 days (Online Figure IC) . When we looked at other 14q32 microRNAs, we observed that more than half the cluster members were upregulated during effective neovascularization. When we include the opposite strands known to have microRNA functions as well, 13 14q32 microRNAs were already upregulated 24 hours after ischemia (early responders); 39 14q32 microRNAs were first upregulated 72 hours after ischemia (late responders); 23 14q32 microRNAs were not regulated at all (nonresponders); and 11 14q32 microRNAs were not on the microarray (Online Table VI) .
For further studies, we chose to investigate 1 14q32 microRNA from each responder group, that all were predicted to target multiple neovascularization genes. We selected miR-494 (early responder), miR-329 (late responder), and miR-495 (nonresponder). miR-487b was the second-most significantly upregulated 14q32 microRNA (early responder). Although it was not identified in either RTP, we did previously report that miR-487b plays an important role in outward remodeling of the aorta, 26 and therefore we also included miR-487b in our further studies. Expression of these 4 14q32 microRNAs was measured in various murine tissues using reverse transcription quantitative polymerase chain reaction (Online Figure II) .
Regulation of these 4 14q32 microRNAs, of microRNAs previously linked to neovascularization, and of the top 9 non14q32 microRNAs identified in RTP1 and RTP2 is shown in Online Figure I .
Gene Silencing Oligonucleotides
We compared the efficacy and specificity of GSOs 23 to the more commonly used antagomirs, using cultures of primary human umbilical arterial myofibroblasts. At a concentration of 10 ng/μL, both antagomirs and GSOs proved equally potent in inhibiting expression of their target microRNA in myofibroblasts. Also, both types of microRNA inhibitors showed a high specificity for their target microRNA (Figure 2A and 2B). However, at higher concentrations (15 ng/μL), signs of cytotoxicity were observed (Online Figure IV) . These effects were subtle for GSOs, but very outspoken for antagomirs. Therefore, we performed our further in vitro studies using GSOs only, at a concentration of 10 ng/μL.
In Vivo MicroRNA Inhibition
We used reverse transcription quantitative polymerase chain reaction to confirm downregulation of the targeted 14q32 microRNAs in the adductor muscles of GSO-treated mice. All 4 GSOs achieved knockdown of their target microRNA at day
GSO Biodistribution
To investigate the biodistribution of GSOs after intravenous injection with or without the induction of HLI, IRDye 800CW-labeled GSO-329 was visualized after injection. Already <1 hour after injection, high dye intensities could be measured throughout the entire mouse ( Figure 3A) . Uptake of GSOs was clearly visible in all organs and tissues, including blood vessels (aorta and vena cava, but not in the brain, which was then used to normalize dye intensities as a measure of tissue uptake; Figure 3J ). Although present, the dye signal in both the adductor and calf muscles was very weak (Figure 3C , 3E, and 3G). However, in animals subjected to HLI 24 hours after GSO injection and euthanized at 48 hours after injection, major uptake of GSOs was observed in both the adductor and calf muscles, but only in the operated paw ( Figure 3B, 3D, 3F , and 3H). Although GSOs were readily taken up into the liver, the feces at 48 hours did not contain any label. However, both kidneys and urine at 48 hours gave very high dye intensities, indicating that GSOs are cleared predominantly via the kidneys. Although intensities dropped slightly in most organs at 48 hours compared with 1 hour after injection, dye intensities were still high throughout the body after 48 hours, indicating slow clearance, which supports the prolonged inhibition of microRNAs that we observed in the adductor muscle of mice subjected to HLI.
Blood Flow Recovery In Vivo
Mice were given a bolus injection of 1 mg GSO in PBS, or PBS alone, via the tail vein. The next day, they were subjected to double ligation of the left femoral artery, a model for severe peripheral artery disease. Blood flow recovery to the paw was followed by LDPI ≤17 days after HLI. Mice in all groups appeared healthy, and no significant weight loss was observed. All 4 treatment groups, GSO-329, GSO-487b, GSO-494, and GSO-495, showed drastically improved blood flow recovery compared with both PBS and GSO control groups ( Figure 4A-4D ). There were no significant differences between PBS and GSO control groups. Mice that received either GSO-329 or GSO-495 showed an increase in perfusion compared with GSO control as early as 3 days after induction of ischemia. The increase in perfusion persisted over time in both groups, and mice treated with GSO-329 even made a full recovery in paw perfusion within an astounding 7 days after induction of ischemia, compared with ≈60% recovery in GSO control-treated mice ( Figure 4A and 4E ). Mice treated with GSO-495 or GSO-494 had nearly fully recovered perfusion after 10 days followed by mice treated with GSO-487b at 2 weeks. The GSO control and PBS groups did not make full recoveries before being euthanized at day 17.
Collateral Artery Diameter Increase
In addition to the increased blood flow recovery observed in animals treated with GSO-329, GSO-487b, GSO-494, and GSO-495, we determined the number and diameter of arterioles by analyzing α-smooth muscle actin-positive vessels in the adductor muscles of GSO-treated mice euthanized 7 days after double ligation of the left femoral artery. Collateral arteries form from preexisting arterioles. Therefore, we were not surprised that the number of collateral arteries between the left and right paw either within groups, or between groups, were similar in all groups, except for GSO-487b ( Figure 5A ). However, we did observe increases in arteriole diameters between the left and right adductor muscles compared with the GSO control for mice treated with GSO-487b (3-fold; P=0.02). Arteriole diameters also appeared increased in mice treated with GSO-329 (2.6-fold; P=0.09), GSO-494 (1.9-fold; P=0.3), and GSO-495 (2.3-fold; P=0.3), indicating GSO-induced increases in arteriogenesis ( Figure 5B ). When we quantified both arterioles with a diameter smaller and a diameter larger than 20 μm, we observed a significant decrease in the number of small arterioles in the left compared with the right paw of mice treated with GSO-329 and GSO-487b ( Figure 5C ) and a trend toward an increase in the number of large collaterals for all 4 GSOs (Figure 5D ), clearly indicating remodeling of small collateral arterioles into larger collateral arteries. 
Increase in Capillary Density
The left (ischemic) and right (normoxic) soleus muscles of GSO-treated mice euthanized 7 days after double ligation of the left femoral artery were stained for CD31 to visualize capillary formation. Increases in capillary formation compared with mice treated with GSO control were observed in the left solei of mice treated with GSO-329 (5-fold), GSO-487b (4-fold), and GSO-495 (4-fold). Capillary formation also appeared increased in the left solei of mice treated with GSO-494 (2.5-fold), but this was not significant (Figure 6 ).
In Vivo Target Gene Regulation
We selected the 14q32 microRNAs for their potential to target a broad range of proarteriogenic and proangiogenic target genes. Because it would not be feasible to confirm regulation of all putative targets, we made a selection based on the number of target sites, conserved between humans and mice, in the 3′ untranslated regions of potential 14q32 microRNA targets (Online Table V ). As we have previously shown, miR-487b has only 14 conserved putative target genes. We confirmed that miR-487b directly targets the vasoactive insulin receptor substrate 1 in the arterial wall, leading to increased survival of both smooth muscle cells and myofibroblasts. 26 For miR-329, we selected Tlr4, 27 Mef2a, [20] [21] [22] 33 and Tgfbr. 34 We used reverse transcription quantitative polymerase chain reaction to determine whether these genes were upregulated in the left adductor muscles of mice treated with the relevant GSOs. In the adductor muscles of mice treated with GSO-329, we observed upregulation of several target genes for miR-329, including Tlr4, Vegfa, and Fgfr2 at 3 days, and Mef2a and Fgfr2 at 7 days after HLI ( Figure 7A and 7B) . In mice treated with GSO-494, we observed upregulation of target genes Tlr4 and Vegfa at day 3 and of Tlr4 (P=0.07), Arf6, Efnb2 (P=0.07), and Fgfr2 at day 7 after HLI ( Figure 7C and 7D) . Because miR-329 was a late responder, the strongest benefits of miR-329 inhibition were expected to be observed early after HLI, in contrast to miR-494, which as an early responder was upregulated rapidly after HLI, and therefore, benefits of inhibition were expected to be observed at later time points. We used both in vitro studies in human primary myofibroblasts and dual luciferase reporter gene assays to determine whether the regulated target genes are also targets for miR-329 and miR-494 in humans. We found that human MEF2A is a direct target for hsa-miR-329, whereas human FGFR2, VEGFA, and EFNB2 are direct targets for hsa-miR-494. VEGFA was found to be regulated by hsa-miR-329, but not via direct binding of hsa-miR-329 to the VEGFA 3′ untranslated region (Online Figure VI) . Although miR-495 was efficiently downregulated and we observed stimulatory effects of GSO-495 on neovascularization and blood flow recovery, we could not confirm upregulation of putative target genes in mice treated with GSO-495 via reverse transcription quantitative polymerase chain reaction (Online Figure VII) .
In Vitro Effects of 14q32 MicroRNA Inhibition
Whereas angiogenesis depends mainly on activation and proliferation of endothelial cells alone, arteriogenesis requires activation and proliferation of arterial endothelial cells, smooth muscle cells, and myofibroblasts. Therefore, we studied the effect of GSO treatment on these 3 cell types. Using FITClabeled GSOs, we observed that GSOs are readily taken up into all 3 cell types within several hours, without the need for any transfection agent ( Figure 8A-8C) . In arterial endothelial cells, inhibition of miR-329, miR-487b, and miR-495 all led to increased cell proliferation by ≈20%, 50%, and 35%, respectively. Inhibition of miR-494 did not affect endothelial cell proliferation ( Figure 8D ). In contrast, in myofibroblasts we observed an increase of 20% in cell proliferation after miR-494 inhibition ( Figure 8E ), whereas no effects were observed for the other GSOs. None of the GSOs had effects on proliferation of smooth muscle cells ( Figure 8F ), as we had previously shown for GSO-487b. 26 We performed an aortic ring assay to determine GSOinduced sprout formation ex vivo. We observed that inhibition of all 4 selected 14q32 microRNAs with GSOs led to increased sprout formation compared with GSO control (Figure 8G-8L ).
Discussion
In this study, we show that inhibition of individual 14q32 microRNAs improves blood flow recovery and stimulates both arteriogenesis in the adductor muscle and angiogenesis in the ischemic calf muscle. We made use of their master switch character to identify microRNAs that regulate neovascularization via RTP. In a total set of ≈200 genes associated with both angiogenesis and arteriogenesis, there was enrichment for binding sites of 27 microRNAs that all belong to the microRNA gene cluster on human chromosome 14. 14q32 microRNAs are upregulated during effective neovascularization in mice. We used GSOs to inhibit Although previous studies have demonstrated beneficial effects of individual microRNA inhibition on postischemic neovascularization, the effect size observed here, particularly for miR-329, is unprecedented. In 2009, Bonauer et al 9 reported on the role of the miR-17/92a cluster in angiogenesis. They showed that inhibition of miR-92a improved postischemic blood flow recovery in C57Bl/6 mice. Although the authors do not report the actual percentages of blood flow recovery, their LDPI images clearly show that mice have not recovered at day 14 after double ligation of the femoral artery and vein. In 2011, Grundmann et al 7 showed that inhibition of miR-100 also leads to improved blood flow recovery after ischemia. The authors described an absolute increase in perfusion of 10% to 15% at day 7 after double ligation of the femoral artery in C57BL/6 mice. Finally in 2012, Yin et al 10 took an opposite approach and demonstrated that overexpression of miR-15a attenuates postischemic blood flow recovery, resulting in an absolute decrease of perfusion of 10% at day 7 and 25% at day 14 after excision of the femoral artery, compared with control animals.
Using a large-scale RTP to identify microRNAs that regulate neovascularization, or any physiological process for that matter, is a novel approach. For neovascularization, the RTP proved both a robust and effective method. We recovered most microRNAs previously reported to be associated with angiogenesis and identified a large set of novel neovascularization microRNAs, the 14q32 microRNA gene cluster. The fact that inhibition of 14q32 microRNAs indeed increases blood flow recovery after ischemia and enhanced both arteriogenesis and angiogenesis in vivo supports the validity of this novel method.
Interestingly, however, we did recover not only microRNAs previously reported to inhibit neovascularization but also microRNAs previously reported to enhance neovascularization, including miR-106b/93/25 8, 14 and miR-424, 25 although miR-424 has also been reported to have antiangiogenic effects. 35 Our list of target genes consisted mainly of proarteriogenic and proangiogenic genes; microRNAs predicted to target these genes are, therefore, likely to inhibit neovascularization. Perhaps, regulation of proneovascularization and antineovascularization pathways is more tightly intertwined than previously thought. This finding also indicates that the RTP could be used to identify proarteriogenic microRNAs, targeting antiarteriogenic genes. Neovascularization could potentially be improved by the use of microRNA mimics, leading to overexpression of these microRNAs and downregulation of their antiarteriogenic targets. However, microRNA overexpression by use of, for example, microRNA mimics is likely to lead to more off-target effects than inhibition, because microRNA overexpression and hence gene inhibitory activity in organs and tissues not endogenously expressing the targeted microR-NA can likely occur.
Although several microRNA target gene prediction algorithms are available online, we chose to restrict our RTPs to www.targetscan.org. In a previous study on polymorphisms in microRNA-binding sites, we found predictions made by TargetScan to have ≈60% accuracy 36 ; combined with the large number of genes included in the RTP, TargetScan's predictions alone proved robust enough to identify important neovascularization microRNAs. Microarray analyses showed upregulation of most 14q32 microRNA gene cluster members during effective neovascularization, which further validates the findings of both RTPs.
The 14q32 microRNA gene cluster is highly conserved between humans and mice. Of the 4 14q32 microRNAs selected for in vivo silencing here, only the sequence of hsa-miR-329 varied slightly from its murine variant mmu-miR-329 (Online  Tables VA-VE ). Yet, many putative binding sites were conserved between humans and mice. Surprisingly, miR-495, which had the most putative proarteriogenic and proangiogenic targets in RTP1, had the least conserved target sites of the 4 selected microRNAs. Because conservation over species often reflects the biological significance of genomic sequences, perhaps this lower degree of conservation explains the more moderate effects of miR-495 inhibition on neovascularization as measured by immunohistochemistry. It may also explain why miR-495 was not regulated during effective vascular remodeling and neovascularization in mice, why it had less putative targets in the evidence-based RTP2, and why we could not confirm upregulation of putative target genes after GSO-495 treatment.
miR-487b is an exceptional microRNA because it has only 14 conserved putative target genes in both humans and mice. We previously confirmed the role of miR-487b in outward remodeling of the aorta, via targeting the prosurvival factor insulin receptor substrate 1 in vivo in rats and in vitro in human primary arterial cells. 26 Having only a single conserved neovascularization target gene, insulin receptor substrate 1, most likely explains the slightly more moderate effects of miR-487b inhibition on blood flow recovery and neovascularization compared with miR-329 and miR-494 inhibition. A recent study on the role of miR-487b in human lung cancer did confirm SUZ12, BMI1, WNT5A, and KRAS as direct targets for miR-487b. 37 However, except for 1 of 2 sites in the Wnt5a 3′ untranslated region, the binding sites for miR-487b in these genes were not conserved in mice and can, therefore, not have contributed to the effects on neovascularization in our murine model.
We set out to identify microRNAs that act as master switches, having perhaps only moderate effects on expression levels, but of many different target genes, involved in all aspects of neovascularization. Particularly miR-329 and miR-494 proved to regulate most of the selected target genes in vivo. These target genes, involved in various aspects of vascular remodeling, were upregulated in vivo after miR-329 or miR-494 inhibition. Correspondingly, effects on blood flow recovery, arteriogenesis, and angiogenesis were robust. Inhibition of miR-329 resulted in an unprecedented rapid recovery of paw perfusion. Because miR-329 was late responder in our microarray analyses, perhaps miR-329 inhibition in the early stages of neovascularization greatly enhances the process as a whole. This hypothesis is supported by the observation that endothelial cell proliferation was enhanced after treatment with GSO-329, because arteriogenesis is initiated after shear stress-induced endothelial activation. miR-329 was recently reported to inhibit pathological angiogenesis via downregulation of CD146, which can act as a coreceptor of the VEGF receptor 2. 39 Like miR-329, inhibition of miR-495 also led to increased paw perfusion in the early stages of postischemic neovascularization. Beside the here-shown increased proliferation of endothelial cells after miR-495 inhibition, previous studies have also shown a role for miR-495 in both cell survival and migration. [39] [40] [41] Inhibition of miR-487b also increases endothelial proliferation.
Our microarray analyses showed that expression of miR-494, after a rapid upregulation, starts to normalize within a week after ischemia. Of the 4 GSOs used in this study, GSO-494 is the slowest starter with respect to blood flow recovery, but especially between days 7 and 10 after femoral HUAFs (E), and primary HUASMCs (F) after GSO treatment (10 ng/μL) measured by 3H-thymidine incorporation relative to GSO control. Data are presented as mean±SEM and represent at least 3 independent experiments. G to K, Outgrowth of neovessels from 5-day collagen-embedded murine thoracic aortic ring explants treated with GSOs. L, Quantification of neovessels. Data are presented as mean±SEM and represent at least 2 independent experiments with 4 rings per condition. *P<0.05, **P<0.01 compared with GSO control.
artery ligation, GSO-494 treatment improves paw perfusion compared with the control. miR-494 was previously reported to impact both proliferation and survival of, among other cell types, cardiac myocytes. 42, 43 We observed that miR-494 did not impact arterial endothelial cell proliferation, but enhanced arterial myofibroblast proliferation, which is in agreement with the slow start followed by stronger increases in flow, particularly in the later stages of neovascularization (ie, myofibroblast recruitment and reinstatement of the extracellular matrix), that we observed in vivo. Potentially, combined administration of GSO-329 and GSO-494 would, therefore, enhance postischemic blood flow recovery and neovascularization even further.
In conclusion, we here demonstrated that inhibition of individual 14q32 microRNAs leads to increases in postischemic blood flow recovery in vivo. We think that 14q32 microRNAs function as master switches in vascular remodeling and neovascularization. Inhibition of either individual, or of a combination of, 14q32 microRNAs may offer a future alternative to growth factors in therapeutic neovascularization.
